A phase III, double-blind, placebo-controlled, monotherapy study of imeglimin (TIMES 1)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2018
At a glance
- Drugs Imeglimin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms TIMES 1
- Sponsors Cmic; Poxel; Sumitomo Dainippon Pharma
- 10 Jul 2018 According to a Poxel media release, efficacy data readout from this trial is expected in the second quarter of 2019.
- 03 Jul 2018 Status changed from recruiting to active, no longer recruiting, according to a Poxel media release.
- 25 Jun 2018 According to Poxel media release, data from this trial are expected in the first half of 2019.